PDS Biotechnology: Late-Stage Biotech With Enormous Potential [Seeking Alpha]
PDS Biotechnology Corporation (PDSB)
Last pds biotechnology corporation earnings: 11/7 06:00 am
Check Earnings Report
Company Research
Source: Seeking Alpha
banjongseal324/iStock via Getty ImagesPDS BiotechnologyNASDAQ:PDSBPDS0101 and PDS0301. In particular, there are two programs in the pipeline which I believe could add long-term shareholder value, should they ultimately succeed. The first of these programs would be the use of PDS0101 in combination with Keytruda for the treatment of patients with human papillomavirus [HPV] 16-positive recurrent or metastatic head and neck cancer. It received clearance from the FDA to begin a phase 3 study using this combination to treat this patient population. However, it has to submit an updated IND for this trial in Q3 of 2023 and then doesn't expect to initiate this late-stage registrational study until Q4 of 2023. In addition,it licensedMerck KGaA(OTCPK:MKKGY) a fusion protein asset known as PDS0301. This was an important license for the fact that it is being used in a triple combination trial. That is, PDS0301 added together with PDS0101 plus an approved immune checkpoint inhibitor [ICI] in a pha
Show less
Read more
Impact Snapshot
Event Time:
PDSB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PDSB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PDSB alerts
High impacting PDS Biotechnology Corporation news events
Weekly update
A roundup of the hottest topics
PDSB
News
- PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- PDS Biotechnology Co. (NASDAQ: PDSB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.MarketBeat
- PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results [Yahoo! Finance]Yahoo! Finance
- PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial ResultsGlobeNewswire
- NetScientific: Significant Advancement with Strategic Goals [Yahoo! Finance]Yahoo! Finance
PDSB
Earnings
- 11/14/23 - Beat
PDSB
Sec Filings
- 3/28/24 - Form S-8
- 3/28/24 - Form 10-K
- 3/27/24 - Form 8-K
- PDSB's page on the SEC website